Work

Abstract CT511: A phase 1 trial of AMP945, a potent and selective focal adhesion kinase inhibitor, in healthy volunteers

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct511

Authors: John Lambert, Christopher J. Burns, Mark Devlin, Nicole Kruger, Jason Lickliter, Mark Sullivan, Warwick Tong

Language: English

Topic: Cell Adhesion Molecules Research

Subfield: Immunology and Allergy

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282963168

Cites:

Cited by: 5

Related to: 10